Jakubowitz Law
(212) 867-4490
Business Minds. Legal Insight.

We combine large firm expertise with small firm attention. Our clients can expect the best results and the most personal experience.

Jakubowitz Law IS HERE TO HELP SHAREHOLDERS WHO PURCHASED Sorrento Therapeutics, Inc. (SRNE)

Sorrento is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s initial finding of “100% inhibition” in an in vitro virus infection will not necessarily translate to to success or safety in vivo, or in person; (ii) the Company’s finding was not a “cure” for COVID-19; and (ii) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you incurred a loss on SRNE stocks purchased between May 15, 2020 and May 22, 2020, this lawsuit is on your behalf. The lawsuit was filed in the the United States District Court for the Southern District of California, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until July 27, 2020 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.

Fill out the form below to be contacted by a representative of Jakubowitz Law.

Loss Submission Form

See If you Qualify for Monetary Reward

Jakubowitz Law does not share your information with others.
There is no cost or obligation for you to submit

This submission does not create an attorney-client relationship.
If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss
whether to establish an attorney-client relationship.